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Excessive antibiotic use is a challenging topic because of the total annual expenditure and the high 
resistance against antimicrobials in Turkey. A point-prevalence study was performed to evaluate the 
daily antibiotic consumption and the cost. Data were collected by infectious diseases consultants on 30 
January, 2009 and 28 January 2010. Anatomical therapeutic chemical classification and the defined 
daily dose (DDD) methodology were used to calculate antibiotic consumption. On a specific day in 
2009, 191 of 418 patients (45.6%) received antibiotics and on the specific day in 2010, 167 of 316 
patients (52.8%) received antibiotics as well. With respect to the years antimicrobials were given 
empirically (41.9 and 38.3%, respectively). The percentage of antibiotics used appropriately was 70.2 
and 71.3%, in 2009 and 2010 respectively. The mean total antibiotic consumption was 64.5 DDD/100 
bed-days in 2009 and 70.46 DDD/100 bed-days in 2010. The most frequently used substance class was 
cephalosporins (16.75 and 24.14 DDD/100 bed-days, respectively). The cost of all used antibacterials 
during the study period in 2009 was 5,713.7 € for all patients (29.9 € per infected patient). In the study 
period of 2010, the total cost was 4,240.13 € (25.39 € per infected patient). The cost of all used 
antimycotics for the combined study periods of 2009 and 2010 was 623.74 and 920.62 €, respectively. 
Hospitals should follow and evaluate their antibiotics use as DDDs so they could compare their 
antibiotics use with hospitals from other countries. 
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INTRODUCTION 
 
The surveillance of antimicrobial consumption is one of 
the most important issues that must be considered to 
improve the quality of antimicrobial use (Papova et al., 
1997). Antimicrobial agents are among the most costly 
categories of drug expenditures in hospitals. They 
account for up to 20 to 30% of the total cost of drugs 
(Pestotnik et al., 1996; Vlahovic-Palcevski et al., 2004). 
The total annual expenditure of antimicrobials in Turkey 
in 2002 was 24% of all drug expenditures (Hosoglu et al., 
2005). However, it is  accepted  that  the  majority  of  this 
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consumption is irrational. Irrational antibiotic use has 
been considered a common problem in Turkey. Despite 
its importance, there is very little available information 
about hospital antibiotic consumption in Turkey (Hosoglu 
et al., 2005). 
The recommended standard unit for measuring 
antibiotic consumption in hospitals is defined as daily 
dose (DDD) per 100 bed-days. The use of this standart 
unit of measurement is based on the promotion made by 
the World Health Organization (WHO) (WHO, 2010). The 
WHO-assigned DDD is the assumed average 
maintenance dose per day for a drug used for its main 
indication. Definitions of DDD are updated on a yearly 
basis. Expressing antibiotic use by using the ‘DDD per 
100 bed-days’ unit is thought to allow hospitals to 
compare their antibiotic use with  that  of  other  hospitals, 
 
 
 
 
 
regardless of differences in formulary composition, 
antibiotic potency, and hospital census (Kuster et al., 
2008; Muller et al., 2006).  
The objective of this study is to evaluate the expen-
diture and pattern of antibiotic consumption in a university 
hospital in Turkey.  
 
 
MATERIALS AND METHODS 
 
Setting 
 
Pamukkale University Hospital is a 352-bed tertiary-care training 
hospital. Four intensive care units (ICU) (Anesthesiology and 
Reanimation ICU, Neurosurgery ICU, Cardiovascular Surgery ICU, 
and Newborn ICU) and 25 other units are assigned to different 
departments.  
 
 
Data collection 
 
In this study, data were collected from ‘medical’ (cardiology, 
endocrinology, gastroenterology, haematology, oncology, 
nephrology, infectious diseases, neurology, paediatrics, physical 
therapy and rehabilitation, pulmonology, psychiatry, dermatology, 
and rheumatology); ‘surgical’ (general surgery, cardiovascular 
surgery, gynaecology and obstetrics, neurosurgery, orthopaedics, 
paediatric surgery, otolaryngology head and neck surgery, plastic 
surgery, thoracic surgery, ophthalmology, and urology), and 
‘intensive care unit (ICU)’ (paediatric ICU, anaesthesiology and 
reanimation ICU, cardiovascular ICU, and neurosurgery ICU). On 
the days of the study, none of the patients in the psychiatry, 
dermatology, rheumatology, or ophthalmology departments were 
using antibiotics. A modified point-prevalence study design was 
used. All wards were surveyed once on the study day. Data on the 
use of antimicrobial agents in the hospital were collected by 
infectious diseases consultants on 30 January, 2009, and 28 
January, 2010. All patients who received antimicrobials, for any 
reason, were included in this study. The data were collected for 
each department from the patients’ charts, using a standard form. 
For each patient receiving anti-infectives, the demographic data, 
results of microbiological tests, diagnosis, name, and dosage of the 
anti-infectives were recorded on the form. After a week, the 
incomplete data were also recorded in the patients’ charts. 
Presence of an infectious disease was diagnosed according to 
signs and symptoms and non-microbiological and microbiological 
laboratory findings, and defined as proven infection. The Centers 
for Diseases Control (CDC) criteria and National Nosocomial 
Infections Surveillance System (NNIS) methodology were used for 
the diagnosis of nosocomial infections (NI) (Garner et al., 1988; 
NNIS, 2004). Fever of unknown origin (FUO) was diagnosed 
according to Petersdorf and Beeson criteria (Petersdorf and 
Beeson, 1961). An infectious diseases physician evaluated the 
appropriateness of the antimicrobial prescriptions. The 
appropriateness of the antibiotic therapy was determined using the 
criteria described by Kunin and Jones and by The Sanford Guide to 
Antimicrobial Therapy (Kunin et al., 1973; Jones et al., 1977; 
Sanford et al., 2009, 2010).  
The surgical antimicrobial prophylaxis administration and the 
accuracy of the antimicrobial prophylaxis management were 
analysed in accordance with the international guidelines on the 
types of antibiotics prescribed as well as on the dose, administra-
tion time and duration of the prophylaxis relative to the time of 
surgery (ASHP, 1999; Dellinger et al., 1994). The guidelines 
recommend that an intravenous single dose of an inexpensive, non-
toxic, and limited-spectrum antibiotic be administered within 30 to 
60 min before the first  incision.   Cefazolin   and   cefuroxime   have 
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been accepted by the WHO as the only appropriate choices for 
non-allergic individuals. The only situations in which vancomycin is 
appropriate for surgical prophylaxis are major surgical procedures 
that involve the implantation of prosthetic materials or devices at 
institutions that have a high rate of infections caused by MRSA or 
MRSE. Vancomycin is also appropriate in patients who have a life-
threatening allergy to β-lactam antimicrobials. Repeated dosage is 
recommended when surgery is prolonged beyond two times the 
half-life of the administered antibiotic. 
The Anatomical Therapeutic Chemical (ATC) classification 
system and DDD are recommended by the WHO as a measuring 
units for drug utilisation studies (WHO, 2010). DDDs are 
standardised doses provided as part of the ATC drug classification 
system maintained by the WHO Collaborating Centre for Drug 
Statistics Methodology (WHO, 2010). Antimicrobial and antimycotic 
utilisation was measured in DDDs per 100 bed-days. This index is 
called the antimicrobial consumption index (ACI). ACI is calculated 
by taking the total (inpatient) DDD for a hospital and dividing that 
number by the total number of bed-days for the hospital. The total is 
multiplied by 100 to obtain the   ACI in DDD/100 bed-days.  
In the current study, DDDs for anti-infective agents were listed for 
systemic use [Group ‘J01’ and ‘J02’ (antibiotics for systemic use 
and antimycotics for systemic use)] according to the ATC–DDD 
Index 2010 (WHO, 2010). The costs of antimicrobials were 
calculated by using daily pharmacy prices in Turkish currency 
(Turkish Lira=TL). The total costs were expressed as Euro (€) by 
taking 1 €=2,112.80 TL in 2009 and 1 €=2,091.80 TL in 2010. 
Two-year averages were calculated by using the data for the 
periods 2009 and 2010, and the changes in antibiotic prescription 
between these two periods were expressed as percentage. 
 
 
RESULTS 
 
In 2009, the mean age (±SD) of the patients was 46.9 ± 
24.6 years, and men accounted for 52.4% of the group. 
In 2010, the mean age (±SD) of the patients was 47.98 ± 
23.5 years, and men accounted for 51.5% of the group. 
During this period, NI rates were 17.9% in 2009 and 
13.3% in 2010. In 2009, 191 of 418 patients (45.6%) 
received anti-infectives. In 2010, 167 of 316 patients 
(52.8%) received anti-infectives. The indications of 
antimicrobial therapy were evaluated. With respect to the 
years, antimicrobials were given empirically (41.9 and 
38.3%, respectively), for surgical antimicrobial 
prophylaxis (38.2% and 46.1%, respectively), for medical 
prophylaxis (6.8 and 4.8%, respectively), and according 
to microbiological data (13.2 and 10.8%, respectively).  
The percentages of antibiotics used appropriately were 
70.2% in 2009 and 71.3% in 2010. Antibiotics were used 
inappropriately more frequently in surgical wards (56.6 
and 43.4%, respectively) than in medical wards (11.25 
and 1.8%, respectively) and in ICU (28.6 and 16 %, 
respectively). The timing of the prophylaxis was found 
appropriate in all procedures; however, the duration was 
optimal only in 24.7 and 27.9%, respectively, in all cases. 
In 2009, 37.6% of patients in the medical unit, 47.5% of 
patients in the surgical unit, and 90.3 % of patients in the 
ICU received anti-infectives. In 2010, 31% of patients in 
the medical unit, 80% of patients in the surgical unit, and 
78% of patients in the ICU received anti-infectives. The 
mean total anti-infective consumption rate was 64.5 
DDD/100  bed-days  in  2009  and  70.46  DDD/100  bed-
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Table 1. Consumption of antiinfectives as a total and by ATC group a hospital in Turkey, 2009 and 2010.  
 
Antiinfectives group ATC code 
DDD per 100 bed-days Percentage of total use 
Absolute change (%) 
2009 2010 2009-2010 2009 2010 
Combinations of penicillins, including ß-
lactamase inhibitors 
J01CR 15.75 14.34 -1.41 (-8.95) 24.42 20.35 
    
   
Cephalosporins, first-generation J01DB 5.26 11.49 6.23 (118.4) 8.16 16.3 
Cephalosporins, second-generation J01DC 4.07 5.69 1.62 (39.8) 6.31 8.08 
Cephalosporins, third-generation J01DD 7.42 6.96 -0.46 (-6.2) 11.5 9.88 
Carbapenems  J01DH 11.72 7.1 -4.62 (-39.4) 18.17 10.08 
Aminoglycosides  J01GB 1.8 0.53 -1.27 (-70.6) 2.79 0.75 
Imidazoles J01XD 4.22 5.7 1.48 (35.1) 6.54 8.09 
Glycopeptides  J01XA 7.72 4.75 -2.97 (38.5) 11.97 6.74 
Fluoroquinolones  J01MA 3.25 5.44 2.19 (67.4) 5.04 7.72 
Others antibacterials  2.34 4.53 2.19 (93.6) 3.63 6.43 
Antimycotics  for  systemic use J02A 0.95 3.93 2.98 (313.7) 1.47 5.58 
    
   
Antibacterials and antimycotics for 
systemic use(total) 
 64.5 70.46 5.96 100 100 
 
*ACI: antimicrobial consumption index (DDD per 100 bed-days).  
 
 
 
Table 2. DDDs and ACI* of antiinfectives as a total by clinical units in the survey, 2009 and 2010. 
 
Antiinfectives group 
Medical units Intensive care units Surgical units 
2009 2010 2009 2010 2009 2010 
DDDs ACI DDDs ACI DDDs ACI DDDs ACI DDDs ACI DDDs ACI 
Combinations of penicillins, including  
ß-lactamase inhibitors 
28.05 13.36 24.4 14 2.9 9.4 0.64 2 34.9 20 24.3 22.12 
             
Cephalosporins 19.5 9.28 17.2 9.9 5.2 17 8.7 27 45.3 26 50.1 45.55 
Carbapenems  16 7.62 10 5.8 17 55 5.05 16 16 9.1 7.2 6.55 
Aminoglycosides  0.5 0.23 0.6 0.4 2 6.5 0.4 1.3 5 2.8 0.66 0.6 
Imidazoles 4 1.91 4.4 2.5 1 3.2 2.3 7.2 12.6 7.1 11.3 10.26 
Glycopeptides  11.75 5.6 9 5.2 9 29 1 3.1 11.5 6.5 5.5 5 
Fluoroquinolones  9.4 4.47 9.8 5.6 2.6 8.4 2 6.3 1.6 0.9 5.4 4.9 
Others antibacterials 5.16 2.46 1 0.6 2 6.5 6 19 2.66 1.5 3.3 3 
Antimycotics  for  systemic use 2 0.95 6.43 3.7 2 6.5 6 19 0 0 0 0 
Total 96.36 45.88 82.8 47.58 43.7 140.97 32.1 100.28 130 73.2 108 97.98 
 
 
 
days in 2010 (absolute change, 5.96). Cephalosporins, 
combinations of penicillins (including ß-lactamase 
inhibitors), carbapenems, and glycopeptides had the 
highest consumption rates during the study periods 
(Table 1). When we examined the consumption changes 
in the various classes of antibiotics DDD/100 bed-days, 
first-generation cephalosporin consumption was the 
greatest (showing absolute change of 6.23) (Table 1).  
The daily cost of all analysed antibacterials in the 2009 
and 2010 study periods were 5,713.7 € (29.9 € per 
infected patient) and 4,240.13 € (25.39 € per infected 
patient), respectively. The daily costs of all used 
antimycotics in the 2009 and 2010 study periods were 
623.74 € (103.94 € per infected patient) and 920.62 € 
(92.06 € per infected patient), respectively.  
Using the standard index of DDDs per 100 bed-days, 
antibiotic consumption was 45.88 and 47.58 in the 
medical units, 73.2 and 97.98 in the surgical units, and 
140.97 and 100.28 in the ICUs in 2009 and 2010, 
respectively. In 2009 and 2010, the ICUs showed the 
highest consumption of antibacterials. Consumption in 
the surgical units increased   by   33.85%   while   in   the 
 
 
 
 
 
medical units consumption increased by 3.7%. On the 
other hand, antibiotic consumption decreased in the ICUs 
by 28.86%. In both years, in the DDD/100 bed-days 
ranking, the most frequently used substance classes 
were cephalosporins, penicillins and penicillins-ß-
lactamase inhibitors, and carbapenems (Table 2). 
The daily costs of all analysed antibacterials during the 
2009 and 2010 study periods were 2,346.2 € (29.7 € per 
infected patient) and 1,670.97 € (30.95 € per infected 
patient) in the medical units; 1,237.6 € (44.2 € per 
infected patient) and 989.43 € (41.97 € per infected 
patient) in the ICU; and 2,130.02 € (26.03 € per infected 
patient) and 1,579.74 € (17.93 € per infected patient) in 
the surgical units, respectively. The daily costs of all 
antimycotics used were 310.3 € (103.44 € per infected 
patient) and 890.5 € (149.9 € per infected patient) in the 
medical units and 310.3 € (103.44 € per infected patient) 
and 21.02 € (5.3 € per infected patient) in the ICU during 
the 2009 and 2010 study periods, respectively. 
Antimycotics were not used in the surgical units during 
the 2009 and 2010 study periods. 
 
 
DISCUSSION 
 
In hospitals, antimicrobial use varies broadly, which may 
be partially explained by differences in patient and 
hospital characteristics, antibiotic policies, physicians, 
education, and health care systems (Kuster et al., 2008). 
Over the last 30 years, many surveys have defined the 
worldwide extent of the problem of antimicrobial misuse 
(Vlahovic-Palcevski et al., 2000). The inappropriate use 
of antimicrobial agents in hospitals has resulted in the 
emergence of resistant microorganisms, increased costs, 
and unnecessary exposure of patients to drugs (Vlahovic-
Palcevski et al., 2004; 2007). Anti-infective drugs are the 
drugs used most often (22% of all drugs) in Turkey 
(Usluer et al., 2005). 
To the best of our knowledge, this is the first study in 
Turkey that covers all departments of a hospital to 
calculate antibiotic consumption using the ATC / DDD 
methodology.  
Enhanced antimicrobial surveillance is a key strategy 
that can be used to monitor the amount of antimicrobial 
use (Karabay and Hosoglu, 2008). Antimicrobial con-
sumption indexes have been measured according to the 
descriptions of the WHO for anti-infectives for systemic 
use. For individual hospitals, prescribing is better 
reported according to internal activity, for which WHO 
recommends DDDs per 100 (or per 1,000) bed-days 
(Berrington, 2010). 
The use of the ATC classification system and the DDD 
as measuring unit are recommended by the WHO for 
drug utilisation studies (WHO, 2010). The system is now 
widely used internationally, and the number of users is 
gradually increasing (WHO, 2010). DDDs have been 
used to compare hospitals, as well as countries.  
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Antibiotic use calculated per admissions and per bed-
day complement one another. DDD 100 bed-days has 
been used to compare both out-of-hospital and hospital 
antibiotic use internationally, and such data have been 
useful, both for benchmarking and for illuminating the 
relation-ship between antibiotic use and resistance at a 
national level (Berrington, 2010).  
The rate of antibiotic use among inpatients increased 
from 45.6 to 52.8% in our hospital. In different studies, 
antimicrobial prescription frequency was found to be 
between 14 and 65% in hospitalised patients (Pestotnik 
et al., 1996; Vlahovic-Palcevski et al., 2007; Usluer et al., 
2005; Ozkurt et al., 2005; Mora et al., 2002).  
In our study, NI rates were between 13.3 and 17.9%. 
The prevalence of NI in Europe has been estimated to be 
between 3.5 and 10% (Vlahovic-Palcevski et al., 2007; 
Berrington, 2010). 
Antimicrobial drugs represent a great part of the total 
yearly drug expenditures. Similarly, the cost of antimicro-
bials is a serious problem for the insurance systems in 
Turkey. In this study, the daily expenses of antibacterial 
drugs were 5,713.70 € in 2009 and 4,240.13 € in 2010 
(cost per infected person was calculated as 29.90 € and 
25.39 €, respectively). The daily expenses for 
antimycotics were 623.74 € in 2009 and 920.62 € in 2010 
(cost per infected person was calculated as 103.94 € and 
192.06 €, respectively). The total costs of anti-infectives 
(antibacterials and antimycotics) per infected person 
were calculated as 33.18 € and 30.90 € in this study. On 
the other hand, the decrease in the cost of anti-infectives 
could be related to a decrease in drug prices in Turkey 
(for example, in 2010, the price of teicoplanin 0.4 gr 
decreased from 41.74 € to 32.84 €, and the price of 
cefoperazone 1gr decreased from 12.73 € to 7.51 €).  
The "Antibiotic Resistance; Prevention and Control" 
(ARPAC) Project showed that the range of antibiotic use 
was 129 DDD/100 occupied bed-days (median = 55) in 
European hospitals (MacKenzie et al., 2005). Antibiotic 
use increased by 7.2%, and ACI use increased by 9.24%, 
in our hospital from 2009 to 2010. In the present study, 
ACI increased from 64.5 DDD/100 bed days in 2009 to 
70.46 DDD/100 bed days in 2010. The DDD/100 bed-
days findings of this study were similar to that of South 
and West Europe, but were higher than North, Southeast, 
and Central/East Europe (MacKenzie et al., 2005). 
Surveys carried out in the university hospitals of different 
countries showed ACI as 39 to 85.6 DDD/100 bed days 
(Vlahovic-Palcevski et al., 2000; Vaccheri et al., 2008).  
Inappropriate antimicrobial usage is a worldwide 
problem. In Turkey, an antibiotic restriction policy was 
applied in 2003 to reduce the expenditure of antibiotics, 
based on a directive from the Ministry of Health. 
According to this policy, certain intravenous and expen-
sive broad-spectrum antibiotics were restricted by legal 
regulation, and their use required approval from an 
infectious disease specialist. Previous reports on 
hospitals applying an antibiotic policy had shown that  the 
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rate of the appropriate use of antibiotics increased after 
intervention (Ozkurt et al., 2005; Tunger et al., 2009). 
According to surveillance studies in Turkey, the 
percentages of appropriate antibiotic use were reported 
to be between 45.7 and 91.4% (Usluer et al., 2005; 
Ozkurt et al., 2005, 2009). In some studies conducted in 
other countries, the percentages of appropriate antibiotic 
use were reported to be between 45 and 89 % (Mora et 
al., 2002; Apisarnthanarak et al., 2006; Raveh et al., 
2001). In the present study, the percentages of appro-
priate antibiotic usage within the study days in 2009 and 
2010 were 70.2 and 71.3%, respectively. The problem is 
more serious in ICUs and in surgical departments than in 
medical departments (Usluer et al., 2005). Antimicrobial 
prescription ratios have been reported as higher in ICUs 
than in other hospital departments (Usluer et al., 2005; 
Hartmann et al., 2004). Antibiotic prophylaxis in surgery 
is one of the matters of discussion regarding hospital use 
of antimicrobial agents, as surgical procedures often are 
associated with unnecessary prescriptions of antibiotics 
(Vaccheri et al., 2008). Antibiotics were used inappro-
priately more frequently in the surgical wards (56.6 and 
43.4%, respectively) than in the medical wards (11.25 
and 1.8%, respectively) and ICUs (28.6 and 16%, 
respectively) in our hospital. In our study, the timing of 
the prophylaxis was found appropriate in all procedures, 
but the duration was optimal only in 24.7 and 27.9% of all 
cases, respectively. In a study conducted in our hospital 
2002 and Yalcin et al. (2007) found that, although the 
timing of the prophylaxis was appropriate in all 
procedures, the duration was optimal only in 29.0% of all 
cases. There was no change in the duration of surgical 
prophylaxis for about eight years in our hospital. A 
national guideline for the surgical prophylaxis would be 
useful for improving the local consensus regarding 
guidelines and for increasing the quality of antibiotic use. 
There are surgical prophylaxis guidelines in some Turkish 
hospitals, but currently there is no national guideline. 
Unfortunately, our hospital does not have any local 
guidelines on surgical antibiotic prophylaxis. To ensure 
the correct and restrictive use of antibiotics, the develop-
ment of hospital guidelines for rational antibiotic use is 
now being included in our hospital’s infection control 
program.  
The antibiotic consumption rate is higher in Turkey than 
in many European countries, such as Sweden, Denmark, 
Germany, and Hungary (Muller et al., 2007). Penicillin 
consumption is higher in Turkey and, compared with 
other European countries, cephalosporin, 
fluoroquinolone, and macrolide consumption rates are 
also very high (Karabay and Hosoglu, 2008). The 
increasing use of fluoroquinolones and cephalosporins is 
alarming, given that they may increase the risk of the 
emergence of resistant microorganisms (Sener et al., 
2007). In the ARPAC Project, it was found that in all 
hospitals, penicillin beta-lactams were used most often, 
followed by non-penicillin beta-lactams and quinolones 
(MacKenzie, 2005). In our  study,  cephalosporins  were  the 
 
 
 
 
most frequently used antibiotics, followed by penicillins 
with beta-lactam inhibitors, carbapenems, imidazole 
derivatives, and fluoroquinolones.  
There are some limitations in our study. One of the 
limitations is its single-centre nature. The second limita-
tion of our study is that antimicrobial resistance rates 
were not investigated. Another limitation is that the study 
contains data for only one day of each year. Combining 
this point prevalence ‘detail’ study with a ‘broad-brush’ 
survey of antibiotic consumption over a longer time 
period. Nevertheless, this study, using a simple and 
inexpensive point-prevalence method, revealed several 
differences in antimicrobial drug prescription among the 
various units of the hospital. Point-prevalence studies are 
often used to provide baseline information regarding 
antibiotic consumption in hospital settings. 
In conclusion, hospitals should use the DDDs to make 
international comparisons of their antibiotic use. Hospital 
antibiotic use could be collected and reviewed routinely to 
determine the antimicrobial consumption trend.  
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